MX2023003458A - Nuevos compuestos. - Google Patents
Nuevos compuestos.Info
- Publication number
- MX2023003458A MX2023003458A MX2023003458A MX2023003458A MX2023003458A MX 2023003458 A MX2023003458 A MX 2023003458A MX 2023003458 A MX2023003458 A MX 2023003458A MX 2023003458 A MX2023003458 A MX 2023003458A MX 2023003458 A MX2023003458 A MX 2023003458A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- compounds
- new compounds
- nlrp3
- inflammasone
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108091008099 NLRP3 inflammasome Proteins 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención se refiere a compuestos novedosos para su uso como inhibidores de la producción del inflamosoma NLRP3, en donde tales compuestos son como se definen mediante los compuestos de fórmula (I) (ver Fórmula) (I) y en donde los componentes integrantes R1, R2 y R3 se definen en la descripción, y donde los compuestos pueden ser útiles como medicamentos, por ejemplo, para su uso en el tratamiento de una enfermedad o trastorno que está asociado con la actividad del inflamosoma NLRP3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20382845.4A EP3974415A1 (en) | 2020-09-24 | 2020-09-24 | Nlrp3 modulators |
PCT/EP2021/076164 WO2022063876A1 (en) | 2020-09-24 | 2021-09-23 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003458A true MX2023003458A (es) | 2023-04-19 |
Family
ID=72709314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003458A MX2023003458A (es) | 2020-09-24 | 2021-09-23 | Nuevos compuestos. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230391756A1 (es) |
EP (2) | EP3974415A1 (es) |
JP (1) | JP2023542231A (es) |
KR (1) | KR20230074199A (es) |
CN (1) | CN116323585A (es) |
AR (1) | AR123582A1 (es) |
AU (1) | AU2021346843A1 (es) |
BR (1) | BR112023005214A2 (es) |
CA (1) | CA3192262A1 (es) |
MX (1) | MX2023003458A (es) |
TW (1) | TW202229244A (es) |
UY (1) | UY39434A (es) |
WO (1) | WO2022063876A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024057013A1 (en) | 2022-09-12 | 2024-03-21 | Exscientia Ai Limited | Nlrp3 modulators |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201710851D0 (en) * | 2017-07-06 | 2017-08-23 | Galápagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis |
US11718631B2 (en) | 2017-10-17 | 2023-08-08 | Novartis Ag | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity |
GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
EP3817817A1 (en) | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
JP7320595B2 (ja) | 2018-07-20 | 2023-08-03 | エフ. ホフマン-ラ ロシュ アーゲー | インターロイキン-1活性の阻害剤としてのスルホンイミドアミド化合物 |
MA53388A (fr) | 2018-07-25 | 2021-06-02 | Novartis Ag | Inhibiteurs d'inflammasome nlrp3 |
WO2020037116A1 (en) | 2018-08-17 | 2020-02-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors |
-
2020
- 2020-09-24 EP EP20382845.4A patent/EP3974415A1/en not_active Ceased
-
2021
- 2021-09-23 TW TW110135274A patent/TW202229244A/zh unknown
- 2021-09-23 KR KR1020237013218A patent/KR20230074199A/ko unknown
- 2021-09-23 CN CN202180064525.XA patent/CN116323585A/zh active Pending
- 2021-09-23 JP JP2023518741A patent/JP2023542231A/ja active Pending
- 2021-09-23 AU AU2021346843A patent/AU2021346843A1/en active Pending
- 2021-09-23 MX MX2023003458A patent/MX2023003458A/es unknown
- 2021-09-23 BR BR112023005214A patent/BR112023005214A2/pt unknown
- 2021-09-23 EP EP21777807.5A patent/EP4217346A1/en active Pending
- 2021-09-23 AR ARP210102642A patent/AR123582A1/es unknown
- 2021-09-23 WO PCT/EP2021/076164 patent/WO2022063876A1/en unknown
- 2021-09-23 UY UY0001039434A patent/UY39434A/es unknown
- 2021-09-23 US US18/245,765 patent/US20230391756A1/en active Pending
- 2021-09-23 CA CA3192262A patent/CA3192262A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
UY39434A (es) | 2022-03-31 |
AU2021346843A9 (en) | 2024-02-08 |
KR20230074199A (ko) | 2023-05-26 |
CN116323585A (zh) | 2023-06-23 |
JP2023542231A (ja) | 2023-10-05 |
EP4217346A1 (en) | 2023-08-02 |
BR112023005214A2 (pt) | 2023-04-25 |
AU2021346843A1 (en) | 2023-06-08 |
CA3192262A1 (en) | 2022-03-31 |
EP3974415A1 (en) | 2022-03-30 |
AR123582A1 (es) | 2022-12-21 |
US20230391756A1 (en) | 2023-12-07 |
TW202229244A (zh) | 2022-08-01 |
WO2022063876A1 (en) | 2022-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022014942A (es) | Nuevos compuestos. | |
MX2022013637A (es) | Nuevos compuestos de triazinoindol. | |
MX2022013323A (es) | Compuestos triciclicos como inhibidores de nlrp3. | |
MX2022012896A (es) | Pirrolo[1,2-d][1,2,4]triazin-2-ilacetamidas como inhibidores de la ruta del inflamasoma nlrp3. | |
MX2022012897A (es) | Pirazolo[1,5-d][1,2,4]triazin-5(4h)acetamidas como inhibidores de la ruta del inflamasoma nlrp3. | |
CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
MX2023003459A (es) | Nuevos compuestos. | |
MX2009009623A (es) | Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide. | |
MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
ATE483679T1 (de) | Substituierte cyclohexylessigsäure-derivate | |
MX2023003264A (es) | Inhibidores de cdk y su uso como productos fármaceuticos. | |
MX2023007265A (es) | Inhibidores de cdk y su uso como productos farmacéuticos. | |
MX2023003846A (es) | Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo. | |
BR112015011974A8 (pt) | derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica | |
MX2022009967A (es) | Compuestos para el tratamiento de la infeccion por coronavirus. | |
ATE438617T1 (de) | Substituierte cyclohexyl-1,4-diamin-derivate | |
MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
MX2023003458A (es) | Nuevos compuestos. | |
MXPA05010020A (es) | Derivados de oxamida. | |
MX2023003825A (es) | Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. | |
MX2023010310A (es) | Derivados de 4-alcoxi-6-oxo-piridazina que modulan nlrp3. | |
MX2023010223A (es) | Derivados de 4-amino-6-oxo-piridazina que modulan la nlrp3. | |
MX2023011057A (es) | Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2). | |
MX2023000198A (es) | Inhibidores de atr y usos de estos. |